Project Summary The fundamental goal of the proposed Washington University/Siteman Cancer Center (WU/SCC) NCTN Lead Academic Participating Site UG1 is to 1) foster scientific leadership and mentorship in the NCTN, 2) participate in the development of NCTN therapeutic, correlative, and cancer control trials, and 3) maintain strong accrual to clinical trials across multiple disease sites, including those that are molecularly driven and those for rare cancers. WU/SCC investigators have a long history of enthusiastic participation in the former cooperative group program and continue to play key roles in the current NCTN program, specifically the Alliance for Clinical Trials in Oncology, ECOG-ACRIN Cancer Research Group, and NRG Oncology. WU/SCC will have 4 UG1 co- Principal Investigators comprising the senior leadership team including Nancy L. Bartlett, MD (Professor, Medical Oncology), Premal Thaker, MD (Professor, Gynecologic Oncology), Clifford Robinson, MD (Professor, Radiation Oncology) and Barry A. Siegel, MD (Professor, Radiology). The WU/SCC senior leadership team is composed of four legacy members with extensive cooperative group and NCTN experience (Bartlett, Thaker, Robinson and Siegel). We feel this consistency will bring continued success to the NCTN program. The entire leadership team is committed to providing guidance for an institution-wide NCTN UG1. WU/SCC has consistently demonstrated robust accrual to NCTN trials, accruing 1217 patients between March 2019 and August 2024. During this same interval, 764 patients had biospecimens collected and 32 patients were accrued to advanced imaging studies. The strength of the WU/SCC genomics, proteogenomics, and molecular imaging programs in combination with the large institutional biorepositories position us to make significant and novel contributions to the scientific mission of the NCTN. WU/SCC investigators remain highly invested in NCTN translational and clinical research in AML, lymphoma, lung cancer, breas